Table 1 Summary of HAART regimens and genotypic resistance tests of the patient
Antiretroviral Therapy | Start | End | VL | CD4+ | CD4+(%) | Reason of change |
|---|---|---|---|---|---|---|
Zidovudine | 15/11/93 | 09/12/93 | N.A. | 1196 | 23,2 | no compliance |
Didanosine | 10/12/93 | 28/04/94 | N.A. | 1328 | 24,2 | no compliance |
Zidovudine | 01/07/95 | 07/06/96 | N.A. | 316 | 13,2 | no compliance |
Stavudine | 28/06/96 | 27/02/97 | 1000 | 67 | 5,4 | no compliance |
Zidovudine + lamivudine | 28/02/97 | 02/09/97 | 27000 | 103 | 8,2 | virological failure |
Zidovudine + lamivudine +ritonavir | 03/09/97 | 20/03/98 | 2200 | 251 | 14,2 | virological failure |
Didanosine + nelfinavir +saquinavir | 12/10/98 | 15/07/01 | 248 | 129 | 5,6 | virological failure |
Stavudine + didanosine + lopinavir/r | 24/07/01 | 23/06/04 | 45000 | 259 | 14 | virological failure |
Didanosine + tenofovir + lopinavir/r | 24/06/04 | 09/03/05 | 2800 | 644 | 22 | virological failure |
Didanosine + tenofovir + nevirapine | 10/03/05 | 10/11/05 | 7700 | 465 | 20 | virological failure |
GRT: RTRM: D67N, K70R, V106A, Y181C, T215F, K219Q, F227L; PIRM: L10I, L24I, L33F, M36I/L, I54V, L63P, V82A | ||||||
Abacavir + lamivudine + Fos-Amprenavir/r | 11/11/05 | 11/04/07 | 19600 | 334 | 17 | no compliance |
GRT: RTRM: D67N, K70R, Y181C, M184V, T215F, K219Q; PIRM: L10I, L24I, L33F, M36L, F53L I54V, L63P, G73S, V82A | ||||||
Abacavir + lamivudine + lopinavir/r | 12/04/07 | 12/02/08 | 14800 | 410 | 17 | virological failure |
GRT: RTRM: D67N, K70R, Y181C, M184V, T215F, K219Q; PIRM: L10I, I13V, L24I, L33F, M36L, F53L, I54V, L63P, G73S, V82A | ||||||
Abacavir + lamivudine + darunavir/r + etravirine | 13/02/08 | ongoing | 89700 | 287 | 16 | ongoing |